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arsenic-exposed population. Studies on arsenic-exposed 
population should be designed in order to examine more 
comprehensively the presence and consequences of these 
genetic/epigenetic alterations.
Keywords Arsenic · Epigenetics · Carcinogenesis · 
Epidemiology
Introduction
Arsenic (As) is regarded as a group I carcinogen for 
humans causing tumors in lung, skin, and bladder (IARC 
2012). To date, it is well known that arsenic is carcinogenic 
and its effects were widely studied since the 70s in regions 
of the world characterized by drinking water with high lev-
els of arsenic, even up to 3,000 µg/l, such as Taiwan, Bang-
ladesh, and Chile (IARC 1980, 1987, 2004, 2012). To date, 
the literature indicates that arsenic in drinking water leads 
to a worldwide elevated risk of lung cancer (IARC 2012; 
Dauphiné et al. 2013), bladder cancer (IARC 2012; Lamm 
et al. 2013), and liver and kidney cancer (IARC 2012; Lin 
et al. 2013; Ferreccio et al. 2013).
The major cause of human arsenic toxicity is from 
contamination of drinking water from natural geological 
sources rather than from mining, smelting, and agricultural 
sources (Matschullat 2000). Arsenic contamination in the 
groundwater was reported worldwide (Nordstrom 2002) 
(Table 1). In order to achieve the goal of protecting pub-
lic health, the US EPA has established a health-based non-
enforceable maximum contaminant level goal (MCLG) of 
zero arsenic and an enforceable maximum contaminant 
level (MCL) of 10 µg/l in drinking water (US EPA 2001).
Chronic arsenic exposure is a risk factor for ischemic 
heart disease (Hsueh et al. 1998); blackfoot disease 
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(BFD), a form of severe peripheral vascular disease asso-
ciated with systemic atherosclerosis (Tseng 1977); and 
neurologic deficits in adults and in children (Wasserman 
et al. 2004). Surprisingly, arsenic is also a promising anti-
cancer agent and can be used effectively to treat acute 
promyelocytic leukemia (APL). The US Food and Drug 
Administration approved in September 2,000 the use of 
As2O3 for the treatment for relapsed and refractory APL 
(Cui et al. 2008).
The underlying molecular mechanisms of inorganic 
arsenic-induced carcinogenicity are still to be elucidated, 
especially since inorganic arsenic, unlike other classical 
chemical carcinogens, is not mutagenic at relevant expo-
sure concentrations (Kitchin and Wallace 2008). Several 
mechanisms have been involved in arsenic-induced car-
cinogenesis, such as genotoxicity, induction of oxida-
tive stress and DNA damage, inhibition of DNA repair 
enzymes, tumor promotion, cell proliferation, chromo-
somal aberrations (CA), signal transduction (Galanis 
et al. 2009; Kligerman et al. 2003), inhibition of DNA 
ligase (Li and Rossman 1989), interference with tubulin 
polymerization in the mitotic spindle (Huang and Lee 
1998; Ramírez et al. 1997), and influencing telomere 
length through the stimulation of telomerase reverse tran-
scriptase (Li et al. 2012).
There is a growing interest in epigenetic effects that 
arsenic would exert on human health. Epigenetic mecha-
nisms allow cells to alter their transcriptional activity, 
thereby permitting changes in gene expression without 
altering the sequence of DNA. There is also an increasing 
evidence for epigenetic modulation in response to environ-
mental factors, and its implication in several human dis-
eases such as cancer (Sandoval and Esteller 2012), neuro-
degenerative diseases (Migliore and Coppedè 2009), and 
cardiovascular diseases (Baccarelli and Ghosh 2012) has 
been well established.
Given the large impact that arsenic has on the health 
of a large number of people, a better understanding of the 
mechanisms of arsenic-related carcinogenesis is needed.
Metabolism of arsenic
The carcinogenic capacity of arsenic is still to be eluci-
dated, but it is likely strongly related to its metabolism. 
Inorganic arsenic is absorbed in the gastrointestinal tract 
when ingested through food or drinking water. Pentavalent 
arsenic form (As5) enters cells through membrane trans-
porters such as phosphate transporter (Bun-ya et al. 1996; 
Rosen 2002) while trivalent form (As3) enters the cell by 
aquaglyceroporin channels (Yang et al. 2012). Arsenic 
uptake strongly depends on cell type and on its oxidation 
state; in particular, trivalent forms are more membrane-per-
meable than pentavalent ones (Dopp et al. 2005).
Pentavalent arsenic form (As5) is reduced to As3 by arse-
nate reductase that can be sequestered in intracellular com-
partments or extruded from cells (Dopp et al. 2005). Meth-
ylation is an important step in the conversion of arsenic from 
the inorganic to the organic form. The general scheme of 
reactions is
Table 1  Contamination of water by arsenic in various world regions
ND non-detectable
Country Area/population Sample type Level of As (µg/l) References
Taiwan Southwestern BFD endemic area 97 artesian well water 10–1,100 Kuo (1968)
Northeastern endemic area of chronic 
arsenic poisoning
3901 well water <0.15–3,590 Chiou et al. (2001)
Bangladesh All Bangladesh 6,485 water samples/10,991 >50 Chowdhury et al. (2000a)
272 drinking water samples/34,000 1,000 Chowdhury et al. (2000b)
Chile Region II Water samples 40–860 Ferreccio et al. (2000)
Argentina All Chile Well samples 40–4,500 Arguello et al. (1938)
Córdoba Drinking water 100–2,000 Hopenhayn-Rich et al. (1996)
Japan Niigata Prefecture 34 well water samples ND–3,000 Tsuda et al. (1995)
6 wells ND
17 wells <1,000
11 wells 1,000
Australia Victoria 18 ground water samples 1–12 Hinwood et al. (1999)
30 surface water samples 1–220
170 drinking water samples 1–73
Finland All Finland Well water samples <0.05–64 Kurttio et al. (1999)
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Arsenite is methylated by arsenic-3-methyl transferase 
enzyme (As3MT) with S-adenosyl-L-methionine (SAM) 
as the methyl-donating cofactor (Aposhian 1997), first to 
monomethylarsonous acid (MMA) and subsequently to 
dimethylarsinous acid (DMA). The reduction of MMA5 
to MMA3 is catalyzed by glutathione-S-transferase omega 
(GSTO) (Németi and Gregus 2004). The inorganic arseni-
cals are known to be taken up by the liver, transformed to 
MMA and DMA, and then excreted into urine as pentava-
lent methylated arsenic form (Naranmandura et al. 2006; 
Suzuki et al. 2002). One part only accumulates in biologi-
cal structures rich in keratin, such as hair and nails (Raab 
and Feldman 2005). Absorbed arsenic is mainly eliminated 
in urine, with a half-life of approximately 4 days in humans 
(Gomez-Caminero et al. 2001). Even after cessation of 
arsenic exposure, it was found that about 40–60 % of arse-
nic may be retained in skin, hair, nails, and muscle and 
small amounts may be retained in teeth and bones (ATSDR 
2013), which continues to contribute to arsenic-induced 
toxicity and carcinogenicity.
The key point is that, whatever the pathway of arsenic 
metabolism may be, the balance between the intake and 
excretion of arsenic (or its metabolites) determines the 
level of arsenic load of an individual, irrespective of the 
end products of the metabolic process. This balance in turn, 
coupled with the genetic makeup of the subject, determines 
whether a particular subject will be susceptible to arse-
nic toxicity or not. For example, polymorphisms in genes 
implicated in arsenic metabolism (e.g., in AS3MT) can 
make a person more susceptible to the damaging effects of 
arsenic (Schläwicke Engström et al. 2009).
Genotoxic effects
Molecular mechanisms of As-induced carcinogenicity are 
still to be elucidated. Since the 80s, the literature shows 
that arsenic is able to induce genotoxic effects in a wide 
range of in vitro and in vivo models and in epidemiological 
human studies (Tables 2, 3, 4). Although arsenic is not so 
able in inducing gene mutations (Klein et al. 2007; Kliger-
man et al. 2003; Rossman 1981), it can be considered a 
genotoxic metalloid, since it induces micronuclei (MN), 
DNA strand breaks, sister chromatid exchanges (SCE), CA, 
and aneuploidy (Gebel 2001).
Several mechanisms have been proposed to explain the 
genotoxicity of arsenic, including the induction of oxida-
tive stress and altered patterns of DNA repair (Kitchin 
2001). Experimental observations suggest that arsenic 
genotoxicity is linked to the generation of reactive oxygen 
As5 C 2e ! As3 C MeC ! MMA5 C 2e
! MMA3 C MeC ! DMA5 C 2e ! DMA3
species (ROS) during its biotransformation (Aposhian 
and Aposhian 2006; Huang et al. 2004). Arsenic can also 
induce oxidative damage in proteins and enzymes due to 
its high affinity for their sulfhydryl groups (Hughes et al. 
2011; Wang et al. 2004), leading to the inactivation of 
many enzymes (Akter et al. 2005). Arsenic-mediated oxi-
dative damage in enzymes is also reported to interfere with 
the DNA repair mechanisms by either inhibiting ligation 
or down-regulating the gene expression of DNA repair 
enzymes such as DNA polymerase b (Sinha and Roy 2011).
The mechanisms by which arsenic exerts its effects 
are complex because its metabolism involves more than 
five metabolites, all of which can produce toxic effects 
(Valenzuela et al. 2005). Speciation plays a crucial role in 
determining the genotoxic potential of arsenic (Colognato 
et al. 2007; Hall 2002). The trivalent methylated species of 
arsenic have been reported to be biologically more active 
than its pentavalent forms (Dopp et al. 2010; Thomas et al. 
2001) and are considered the major source of arsenic geno-
toxicity (Kligerman et al. 2003; Mass et al. 2001).
In vitro arsenic genotoxicity studies
Several investigations of arsenic-induced genotoxic dam-
age in human and in animal cells were performed (Table 2).
Arsenic-induced MN in SV-40 immortalized human 
uroepithelial cells (Chai et al. 2007), in human colorec-
tal carcinoma cells (Salazar et al. 2009), and comet assay 
revealed that the treatment of HT-29 colon cells with arse-
nic trioxide (As2O3) caused severe DNA damage (Alar-
ifi et al. 2013; Stevens et al. 2010). Arsenic also induced 
nuclear DNA damage and mutations in mitochondrial DNA 
of human prostate epithelial cells (Singh et al. 2011). It was 
also demonstrated that chronic exposure to arsenic resulted 
in increased cell survival by decreasing the expression of 
pro-apoptotic genes (Singh et al. 2011). Dopp et al. (2011) 
observed by means of comet assay that trimethylarsine 
(Me3As) induced elevated DNA damage only at cyto-
toxic concentrations in human hepatoma and colon cells 
and in hamster ovary cells (Dopp et al. 2011). Moreover, 
a significant dose-dependent increase in DNA damage in 
human promyelocytic leukemia cells and in a human Jurkat 
T-lymphoma cell line after As2O3 exposure was observed 
(Yedjou and Tchounwou 2007; Yedjou et al. 2008). Arsenic 
was also able to induce recombination processes in human 
peripheral blood lymphocyte (PBL) cultures with a dose-
dependent augmentation (Avani and Rao 2007).
Other effects of arsenic on PBL were shown by means of 
comet assay; particularly sodium arsenite, MMA and DMA 
induced weak DNA damage (Sordo et al. 2001). In another 
study, PBL was treated with six arsenic compounds (As3, 
As5, MMA3, MMA5, DMA5, and TMAO5) (Colognato et al. 
2007). All arsenic metabolites induced MN, except DMA5. 
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Table 2  In vitro arsenic genotoxicity studies
"  Increase, CHO Chinese hamster ovary, PBL peripheral blood leukocytes, SHE Syrian hamster embryo
Genotoxic effect As speciation/dose Cell type References
Human cells
" MN 0.5 µM As3 PBL Schaumlöffel and Gebel (1998)
" MN 1–10 µM NaAsO2 SV-40 immortalized human  
uroepithelial cells (SV-HUC-1)
Chai et al. (2007)
" MN 4 µM As3
32 µM As5
2 µM MMAs3
MMAs5 at 500 µM
PBL Colognato et al. (2007)
" MN 0.1, 1 and 10 µM NaAsO2 RKO (human colorectal carcinoma) 
cell line
Salazar et al. (2009)
" MN 0.5 µM MMA3 for 24 h Human A549 epithelial lung  
adenocarcinoma cells
Bartel et al. (2011)
" DNA damage 1.25–80 µM MMA3 and  
1.4–91 µM DMA3
PBL Mass et al. (2001)
" DNA damage >5  106 M NaAsO2, MMA, 
DMA
Human lymphocytes Sordo et al. (2001)
" DNA damage 0.1–10 mM As3 and As5 TK6 human lymphoblastoid cells Guillamet et al. (2004)
" DNA damage 2.5–10 µg/ml As2O3 HL-60 (human promyelocytic  
leukemia) cells
Yedjou and Tchounwou (2007)
" DNA damage 4, 8, and 16 µg/ml As2O3 Human Jurkat T-lymphoma cells Yedjou et al. (2008)
" DNA damage 8 and 10 µg/ml As2O3 HT-29 (human colon cancer) cells Stevens et al. (2010)
" DNA damage NaAsO2 Human prostate epithelial cells 
(RWEP-1)
Singh et al. (2011)
" DNA strand breaks only at  
cytotoxic concentrations
Me3As HepG2 (human hepatoma) cells, 
CHO-9 cells, CaCO (human colon) 
cells
Dopp et al. (2011)
" DNA damage 2.5 µg/ml As2O3 Human hepatocellular carcinoma Alarifi et al. (2013)
" SCE 107–105 M As3 PBL Gebel et al. (1997), Rasmussen 
and Menzel (1997)
" SCE 0.5, 1, and 2 µg As3 PBL Avani and Rao (2007)
" CA As3, As5, DMMA, MMA, and 
TMAO
Human umbilical cord fibroblast Oya-Ohta et al. (1996)
" CA 0–5 µM As3 PBL Mahata et al. (2004a)
Animal cells
" MN 0–80 µM As3 V79 and CHO Gebel et al. (1997), Wang et al. 
(1997)
" MN 1–10 µM DMA3 and 5–7.5 µM 
MMA3 for 24 h
CHO-9 (Chinese hamster ovary)  
cells
Dopp et al. (2005)
" MN 0.025–0.75 µM NaAsO2 Cultured primary Wistar rat  
hepatocytes
Hasgekar et al. (2006)
" DNA damage 50–500 µM As2O3 V79 (hamster Chinese lung—male) 
cells
Roy et al. (2008)
" DNA damage 2–8 µM DMA3 and MMA3 Splenocytes of superoxide dismutase 
knockout mouse model
Tennant and Kligerman, (2011)
" DNA damage 10, 20 µM MMA Primary splenic lymphocytes of  
catalase knockout mouse model
Muñiz-Ortiz et al. (2013)
" SCE As3 tenfold more potent than As5 SHE cells Lee et al. (1985)
" SCE 23 µM As3 V79 cells Helleday et al. (2000)
" CA From 3.8 to 3,700 µM As3, As5, 
DMA, TMAO, arsenocholin, 
arsenobetaine (CH3)4AsI
V79 cells Eguchi et al. (1997)
" CA 0.02 nM thio-DMA for 48 h Syrian hamster embryo cells Ochi et al. (2007)
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MMAs3 showed the highest genotoxic effect, and fluores-
cence in situ hybridization analysis (FISH) revealed that the 
MN induction was due to an aneuploidogenic mechanism 
(Colognato et al. 2007). The different effects induced by 
different arsenic compounds in PBL were also well showed 
by Mass et al. (2001). Trivalent arsenic derivatives pro-
duced significant concentration-related increases in DNA 
damage as shown by the entity of “comet” tail moment, 
with respect to pentavalent one. In a human lymphoblas-
toid cell line, Guillamet et al. (2004) observed that As3 and 
As5 induced DNA strand breaks, while MMA and DMA 
did not. An interesting study was performed (Mahata et al. 
2004a) treating with sodium arsenite (Na3AsO3) PBL of 
six symptomatic (having arsenic-related skin lesions) indi-
viduals, six age- and sex-matched arsenic-exposed asymp-
tomatic (no arsenic-related skin lesions) individuals, and 
six control individuals residing in non-affected districts of 
West Bengal with no evidence of arsenic exposure. In lym-
phocyte cultures of both exposed groups, spontaneous CA 
were significantly higher when compared to the spontane-
ous CA of non-exposed control individuals. After in vitro 
treatment, Na3AsO3 induced a significantly higher percent-
age of aberrant cells in lymphocytes of control individu-
als than in those of both the exposed groups. This could 
be probably due to the long-term exposure to arsenic that 
may have caused in lymphocytes of the exposed group a 
minor response after in vitro treatment than in lymphocytes 
of the unexposed group. This difference in arsenic-induced 
genetic damage may be due to acquired susceptibility or to 
some adaptive variation (Mahata et al. 2004a). In hamster 
lung V79 cells, arsenic induced recombination processes 
(Helleday et al. 2000) and caused severe DNA damage 
(Roy et al. 2008). Furthermore, arsenic induced MN in pri-
mary cultures of rat astrocytes and hepatocytes (Catanzaro 
et al. 2010; Hasgekar et al. 2006). In hamster ovary cells, 
As5 and MMA3 induced elevated numbers of MN while 
the number of micronucleated cells was not significantly 
increased when cells were exposed to MMA5 (Dopp et al. 
2005). To test the hydroxyl radical (–OH) involvement in 
the genotoxic pathway of arsenic, splenocytes from Cu/Zn 
superoxide dismutase (Sod1) knockout mice were exposed 
to As3, MMA3, and DMA3. By means of comet assay, the 
authors observed that MMA3 and DMA3 induced DNA 
damage (Tennant and Kligerman 2011). The same team 
exposed primary splenic lymphocytes and hepatocytes 
collected from catalase homozygous knockout (Cat /) 
mice to MMA3, observing that Cat / lymphocytes are 
more susceptible to MMA3 than the wild-type lymphocytes 
by a small (1.5-fold) but statistically significance differ-
ence; this difference increased to approximately fivefold 
when the authors compared Cat / and Cat +/+ hepato-
cytes exposed to MMA3 (Muñiz-Ortiz et al. 2013). These 
findings support the hypothesis that the oxidative damage 
pathway is an important factor in arsenic ability to induce 
genetic damage. Thiodimethylarsinic acid (thio-DMA5) is 
the pentavalent sulfur analogue of DMA5 and a metabolite 
of organic as well as inorganic arsenicals. In urine samples 
of 75 inorganic arsenic-exposed women in Bangladesh, 
Table 3  In vivo arsenic genotoxicity studies
"  Increase
Genotoxic effect As speciation/dose Tissues/animal model References
" MN SA 0.5–10 mg/kg, administered  
intraperitoneally
Polychromatic erythrocytes of CBA, 
Balb/c and C57BL mice
Tinwell et al. (1991), Deknudt et al. 
(1986)
" MN 0.395–0.630 ppm As Gill cells of zebra fish Ramírez and García (2005)
" MN 50 mg/l NaAsO2 C57BL/6J/Han mice Lewin´ska et al. (2007)
" MN 15 mg/l iAs as NaAsO2 Golden Syrian hamsters Hernández et al. (2011)
" MN 50, 100, and 200 ppm NaAsO2 Ovarian tissue (rat) Akram et al. (2009)
" DNA single-strand breaks DMA/1,500 mg b.w. Lung of CD1 mice Yamanaka and Okada (1994), 
Yamanaka et al. (1989)
" DNA damage Different doses of As2O3 Whole blood in mice Saleha Banu et al. (2001)
" DNA damage As3 Swiss albino mice Sinha et al. (2010)
" CA / Bone marrow cells of Swiss albino 
mice
Roychoudhury et al. (1996), Das et al. 
(1993)
" CA 0.016 % As2O3 (1 ml/100 g b.w.) Mus musculus Banerjee et al. (2007)
" CA Human reference dose  
(0.3 3 µg/kg/day)
Mus musculus Kesari et al. (2012)
" MN and " CA 0.10–1,000 µg/l As2O3 Erythrocytes of Carassius auratus  
and Channa puncatus
Kumar et al. (2013)
" MN and " CA 0.3–15 µg/kg/day Erythrocytes of Swiss albino mice Khan et al. (2013)
Induction of aneuploid cells DMA/300 mg/kg b.w. Bone marrow cells of CD1 mice Kashiwada et al. (1998)
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thio-DMA5 has been shown to be a common metabolite, 
being detected in 44 % of the samples (Raml et al. 2007). 
Investigations on MN induction after thio-DMA cell treat-
ment were conducted (Bartel et al. 2011) showing that the 
induction of micronuclei occurred only at beginning cyto-
toxic concentrations, suggesting that thio-DMA5 does not 
act via a genotoxic mode of action. In cultured hamster 
cells, thio-DMA5 induced severe chromosome structural 
aberrations, such as chromatid gaps, chromatid breaks, and 
chromatid exchanges (Ochi et al. 2007).
In vivo arsenic genotoxicity studies
An important consideration for arsenic-related in vivo stud-
ies is the use of experimental animal models similar to 
humans in terms of arsenic biotransformation ability. Here, 
we review these studies in order to evaluate the arsenic 
genotoxic effects (Table 3).
Administration of Na3AsO3 resulted in a signifi-
cant induction of MN in the ovarian tissue of rats in a 
dose-dependent manner (Akram et al. 2009). A statisti-
cally higher MN frequency was found in bone marrow of 
C57BL/6J/Han mice exposed to arsenic compared with 
controls. This effect was more pronounced after combin-
ing exposure to arsenic and benzo(a)pyrene (Lewin´ska 
et al. 2007). MN frequency in gill cells of zebra fish (Danio 
rerio) and in fish erythrocytes was greater than in the nega-
tive control, demonstrating the genotoxicity of arsenic in 
well water (Kumar et al. 2013; Ramírez and García 2005).
Golden Syrian hamsters received drinking water con-
taining Na3AsO3 or unaltered water. The frequency of 
micronucleated reticulocytes (MN-RETs) was statistically 
Table 4  Ex vivo genotoxic effects studies
"  Increase, !  stable
Genotoxicity biomarkers/cell type Population characteristics References
" MN, both C+ and C (bladder cells) 18 people chronically exposed to high levels (>500 µg/l) Moore et al. (1996)
" MN (bladder cells) 232 people, some exposed to low (15 µg/l) and others 
to high concentrations (up to 670 µg/l) of As in well 
water
Biggs et al. (1997)
" MN, both C+ and C (bladder cells) Chilean male population chronically exposed to high 
(65 subjects/600 µg) and low (39 subjects/15 µg) As 
concentration
Moore et al. (1997)
" MN (oral mucosa and bladder cells) 19 residents exposed to high levels in drinking water 
(50 µg/l–1.8 mg/l)
Tian et al. (2001)
" MN (oral mucosa, bladder cells, and PBL) 45 exposed individuals with cutaneous signs of arseni-
cism (iAs 368.11 µg/l)
Basu et al. (2002)
" MN (oral mucosa, bladder cells, and PBL) 163 residents exposed to high levels in drinking water 
(2,147,213 ± 9.0273 µg/l)
Basu et al. (2004)
" MN (PBL) 106 individuals exposed to 0.750 mg/l As in well water Martínez et al. (2004)
! MN (oral mucosa cells) 105 exposed individuals Martínez et al. (2005)
" CA (PBL) 24 current users (As average in wells 410 mg/l); ten 
stopped users
Mäki-Paakkanen et al. (1998)
" CA (PBL) 25 BD-affected individuals and 25 cases of non-cancer-
ous subjects
Ghosh et al. (2007)
" MN (oral mucosa) and " CA (PBL) Symptomatic group (244 subjects) and non-symptomatic 
group (178 subjects) exposed to high level (>200 µg/l); 
control group (102 subjects) exposed to low level 
(<10 µg/l)
Ghosh et al. (2006)
" MN and " CA (PBL) 45 exposed subjects (levels in drinking water >50 µg 
As/l)
Chakraborty et al. (2006)
" MN (PBL) and " DNA damage (PBL) 124 residents exposed to high levels of As3 in drinking 
water (1–187 µg/l)
Sampayo-Reyes et al. (2010)
" DNA strand breaks (whole blood)  
and " CA (PBL)
60 arsenic exposed (30 individuals with As-induced pre-
malignant hyperkeratosis and 30 without skin lesions)
Banerjee et al. (2008)
! SCE and " CA (PBL) 11 individuals chronically exposed and 13 controls Ostrosky-Wegman et al. (1991)
! SCE and " CA (PBL) 22 cancers cases and 22 controls Liou et al. (1999)
" CA and " SCE (PBL) 59 exposed individuals (211.79 ± 15.28 µg/l) Mahata et al. (2003)
" CA and " SCE (PBL) 165 symptomatic subjects (mean As 214.96 µg/l) Mahata et al. (2004b)
No increased SCE (PBL) 32 cancer cases and 32 control subjects Liou et al. (2002)
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increased in treated animals with respect to the control 
group (Hernández et al. 2011).
Mice administered orally with As2O3 dissolved in dis-
tilled water showed significant increase in comet tail-
length at 24-h post-treatment and a gradual decrease at 
72-h post-treatment, indicating a gradual repair in DNA 
damage (Saleha Banu et al. 2001). Prominent induction 
of DNA fragmentation in a time-dependent manner with 
respect to control was observed in Swiss albino mice 
treated with As3 (Sinha et al. 2010). Wang and collabo-
rators observed that arsenate and dimethylarsinic acid 
(DMA5) in drinking water did not affect DNA damage 
repair in urinary bladder transitional cells or micronu-
cleus formation in bone marrow of rats (Wang et al. 
2009).
Increase in both CA and MN was observed in mice 
exposed to As2O3 (Banerjee et al. 2007; Kesari et al. 2012; 
Khan et al. 2013). CA and MN were induced in mice upon 
exposure to doses equivalent to arsenic human reference 
dose (0.3 µg/kg/day) established by the United States Envi-
ronmental Protection Agency (USEPA) (Kesari et al. 2012; 
Khan et al. 2013). Therefore, at its human reference dose, 
arsenic has been found to induce significant genetic dam-
age in mice.
Ex vivo arsenic genotoxicity studies
In addition to in vitro and in vivo studies aimed to evaluate 
the genotoxic effects induced by arsenic, several epidemio-
logical studies were performed in order to evaluate geno-
toxicity biomarkers among different populations exposed 
to arsenic (Table 4).
Statistically significant association between MN 
frequency and arsenic exposure was found in several 
investigations. In 45 West Bengal exposed individuals 
with cutaneous signs of arsenicism was observed a sta-
tistically significant increase in the frequency of MN in 
oral mucosa exfoliated cells, urothelial cells, and PBL 
when compared to 21 healthy individuals as controls 
(Basu et al. 2002). In a subsequent study, the same team 
observed that the MN frequency of exposed group (154 
subjects) was significantly elevated with respect to the 
control group (154 subjects), and this frequency was 
higher in PBL with respect to oral mucosa and urothelial 
cells (Basu et al. 2004). Similar results were observed 
in individuals from Central West Inner Mongolia (Tian 
et al. 2001) and from northern Chile (Martínez et al. 
2004). One study found no association between MN and 
arsenic levels in drinking water (Martínez et al. 2005). 
Sampayo-Reyes et al. (2010) evaluated DNA damage, 
by comet assay, in PBL of arsenic-exposed inhabitants 
of the north Mexico. The authors found a positive asso-
ciation between the level of exposure and the genetic 
damage measured as percentage of DNA in tail. They 
also observed that AS3MT Met287Thr polymorphism sig-
nificantly influenced the genetic damage among children 
carrying the 287Thr variant allele (Sampayo-Reyes et al. 
2010).
Increase in MN and CA was observed in PBL and oral 
mucosa cells of people chronically exposed to arsenic in 
West Bengal (Chakraborty et al. 2006; Ghosh et al. 2006).
Ghosh et al. (2007) investigated the use of CA as a bio-
marker to predict the Bowen’s disease (BD) (a neoplastic 
skin disease considered as an early stage or an intraepi-
dermal form of squamous cell carcinoma) that can derive 
by hyperkeratosis induced by chronic arsenic exposure. 
Results showed that CA was significantly higher in BD 
cases compared to controls.
In 2003 and 2004, two biomonitoring studies were con-
ducted in a West Bengal region. Results of CA and SCE 
assays showed a significant increase of cytogenetic dam-
age in lymphocytes due to arsenic exposure (Mahata et al. 
2003, 2004b). A study performed in the endemic area for 
BFD in the southern Taiwan reported that the frequency of 
SCE was higher in the case group, although this difference 
was not statistically significant (Liou et al. 2002).
A study explored genotoxic effects, using comet assay 
and CA assay, and DNA repair capacity, with challenge 
assay, in 60 arsenic-exposed individuals (30 individu-
als with arsenic-induced premalignant hyperkeratosis and 
30 without skin lesion) of West Bengal and 30 arsenic 
unexposed individuals (Banerjee et al. 2008). It appears 
that both the exposed groups had similar levels of basal 
arsenic-induced DNA damage. Individuals with arsenic-
induced premalignant hyperkeratosis, however, had sig-
nificantly higher CA in comparison with the group of 
individuals without skin lesions. Challenge assay showed 
that upon induction of DNA damage, the repair capacity in 
the exposed individuals with premalignant hyperkeratosis 
was significantly less than that of individuals without skin 
lesions. This leads to the hypothesis that the DNA repair 
mechanisms in exposed individuals might not be as effec-
tive as that of the unexposed ones, and perhaps this differ-
ence in DNA repair capacity makes those individuals sus-
ceptible to arsenic toxicity and subsequent carcinogenicity 
(Banerjee et al. 2008).
Considering these evidences, we might say that CA 
and MN, as markers of early biological effects of car-
cinogen exposure (Bonassi et al. 2007; Liou et al. 1999), 
seem to be the best biomarkers to identify the pathologi-
cal effects of arsenic in biomonitoring studies (Table 4). 
Regarding the evaluation of MN, buccal cells do not 
seem to be the most suitable target cells to study the gen-
otoxic effects of arsenic exposure with respect to PBL 
and bladder cells (Martínez et al. 2005). Due to the few 
studies available (Banerjee et al. 2008; Sampayo-Reyes 
 Arch Toxicol
1 3
et al. 2010), it is hard to argue the significance that may 
have the evaluation of DNA damage by comet assay in 
biomonitoring studies. However, data indicate that the 
arsenic exposure induces DNA damage. Regarding SCE, 
no significant difference between the frequencies of SCE 
in cancerous and non-cancerous populations recruited 
in the arseniasis area was found (Liou et al. 2002). In 
two epidemiological studies was found an increase in 
SCE frequency in people exposed to arsenic (Mahata 
et al. 2003, 2004b). In view of these conflicting results, 
SCE may not be considered a good biomarker to detect 
the effects of arsenic, as most arsenicals are poor SCE 
inducers.
Aberrant epigenetic mechanisms induced by arsenic 
exposure
Epigenetic refers to the reversible regulation of gene 
expression, occurring independently of DNA sequence 
(Fig. 1). Epigenetic modifications, mediated by DNA meth-
ylation, histone tails modifications, and noncoding RNA 
interventions, render the genome vulnerable toward malig-
nant progression (Bhattacharjee et al. 2013; Guil and Estel-
ler 2009). Chromatin remodeling by epigenetic reprogram-
ming controls the regulation of gene expression and has 
important implications in the development of human can-
cers. Several recent papers highlight the effects of arsenic 
and arsenic metabolites on global and gene-specific DNA 
methylation, as well as the effects of exposure to arsenicals 
on histone modifications, chromatin structure, and micro-
RNA. Results of these studies will be reviewed here.
DNA methylation
The main epigenetic mechanism studied in relation to arse-
nic exposure is DNA methylation (Table 5). Methylation 
refers to the addition of a methyl group to the fifth car-
bon position of a cytosine residue that is followed on the 
same strand by guanine, also known as a CpG dinucleo-
tide. CpG dinucleotides occur in concentrations known as 
CpG islands, and CpG islands can be found in the promoter 
region of approximately half of all human genes (Estel-
ler 2002). In pathologically normal cells, promoter CpG 
islands regions are typically unmethylated. Several mech-
anisms are theorized to underline epigenetic changes in 
DNA methylation by arsenic. Arsenic, by its metabolism, 
affects the activity of DNA methyltransferase (DNMT) 
enzymes (Han et al. 2011). As mentioned above, the bulk of 
circulating arsenic undergoes biotransformation in hepato-
cytes where arsenite is subjected to a series of sequential 
oxidative methylation and reduction steps yielding sev-
eral methylation products (Hughes 2002). These methyla-
tion steps facilitate arsenic excretion but at the same time 
consume S-adenosyl methyionine (SAM) (Fig. 2). SAM is 
generated in one-carbon metabolism that requires homo-
cysteine (Hcy), folate, and other vitamins and cofactors, 
such as cobalamin (vitamin B12), from the diet to function. 
Folate is reduced in the 5-methyltetrahydrofolate (5-methyl 
THF) form that can be used by one-carbon metabolism to 
form SAM as well as to synthesize DNA and RNA precur-
sors. If not used for SAM synthesis, Hcy can be condensed 
with serine to form cystathionine in a reaction catalyzed 
by cystathionine b-synthase (CBS). Cystathionine can be 
then utilized to form the antioxidant compound glutathione 
Fig. 1  Epigenetic mechanisms. 
Actively transcribed genes 
are associated with accessible 
(decondensated) chromatin 
regions while genes that are 
transcriptionally silent are 
often located in inaccessible 
(condensed) chromatin regions. 
DNA methylation can occur 
in CpG sites of gene promoter 
regions; promoter hypermeth-
ylation is commonly associated 
with gene silencing and pro-
moter demethylation with gene 
expression. miRNAs are small 
noncoding RNAs that regulate 
the expression of complemen-
tary messenger RNAs, e.g., 
blocking protein translation
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(GSH) (Coppedè 2010). Cofactors are obtained from die-
tary sources, and therefore, SAM synthesis is susceptible 
to dietary deficiencies of these essential nutrients as well 
as methionine (Bailey and Gregory 1999). Dietary deficien-
cies that limit the supply of SAM are linked to epigenetic 
changes in gene expression and are thought to predispose 
to the transgenerational occurrence of diseases (Coppedè 
2010).
Consumption of SAM during the metabolism of arse-
nic is proposed as an important consequence of exposure. 
This theory suggests that SAM is utilized by arsenite meth-
yltransferase (AS3MT) to methylate arsenic leading to the 
depletion of SAM and accumulation of S-adenosylhomo-
cysteine (SAH) (Caudill et al. 2001; Martínez et al. 2011). 
Furthermore, arsenic exposure in the presence of folate 
nutritional deficiency may facilitate genomic hypomethyla-
tion. Since methylation of arsenic uses SAM as a methyl 
donor, diets deficient in folic acid, methionine, choline, 
and vitamin-B12 can limit the synthesis and reutilization of 
SAM (Davis and Uthus 2004; Pilsner et al. 2009).
It is supposed that methylation of genes can mediate car-
cinogenesis through
s up-regulation of oncogene expression and hence 
genome instability (hypomethylation),
s down-regulation of tumor suppressor genes (hypermeth-
ylation).
Arsenic exposure has been shown to alter methylation 
levels of both global DNA and of several well-known can-
cer gene promoters in in vitro cell cultures, in in vivo ani-
mal models, and in people exposed to arsenic.
The first work aimed to test the hypothesis that arsenic 
carcinogenesis could involve alterations of DNA methyla-
tion was performed in 1997 by Mass and Wang (1997). 
They found that exposure of human lung adenocarci-
noma A549 cells to Na3AsO3 or Na3AsO4, but not DMA, 
produced significant dose-responsive hypermethylation 
within a 341-base-pair fragment of the promoter of TP53 
and hypermethylation of CpG sequences over the entire 
genome (Mass and Wang 1997). By this work onwards, 
several studies have been carried out on various human 
cell cultures in order to observe the arsenic effects at both 
gene-specific and global DNA methylation level. DAPK, 
h-MLH1, DBC1, FAM83A, ZSCAN12, and C1QTNF6 
genes were found hypermethylated after arsenic cells treat-
ment (Chai et al. 2007; Jensen et al. 2008; Treas et al. 
2013). At the same time, gene-specific hypomethylation 
of several genes, such as p16, RASSF1, E-cadherin, and 
GSTP1, was found (Cui et al. 2006a; Du et al. 2012). Fur-
thermore, hypomethylation of protooncogenes c-myc and 
c-Ha-ras was observed in Syrian hamster embryo cells 
(Takahashi et al. 2002). By means of a DNA methylation Ta
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microarray approach, Jensen et al. (2009) analyzed 10350 
promoters in DNA of arsenical-induced malignant transfor-
mation human urothelial cells, observing that both hyper- 
and hypomethylation occur in gene promoter regions with 
hypermethylation being the more prevalent event (Jensen 
et al. 2009). At a global DNA methylation level, arse-
nic induced predominantly hypomethylation in human 
keratinocytes, prostate, and colorectal cell cultures (Ben-
brahim-Tallaa et al. 2005; Coppin et al. 2008; Davis et al. 
2000; Du et al. 2012; Reichard et al. 2007). Global DNA 
hypomethylation was also observed in rat, hamsters, and 
murine cell cultures (Chen et al. 2001; Sciandrello et al. 
2004; Singh and DuMond 2007; Zhao et al. 1997).
Studies in animal models were mainly carried out to 
investigate the effects of arsenic on global DNA meth-
ylation; animals fed with arsenic showed predominantly 
global DNA demethylation (Bagnyukova et al. 2007; Chen 
et al. 2004; Uthus and Davis 2005; Martìnez et al. Martínez 
et al. 2011; Okoji et al. 2002; Xie et al. 2004). However, 
gene-specific investigations were also performed. Cui and 
collaborators (Cui et al. 2006b) observed a dose-related 
hypermethylation of p16 and RASSF1 in mice orally 
administered with As5 with a concomitant increment of 
lung tumor incidence while hypomethylation of Er-  and 
Ha-ras was induced in mice exposed to As3 (Chen et al. 
2004; Okoji et al. 2002). The effects of in utero exposure 
to arsenic on gene-specific methylation, using genome-
wide DNA methylation profiling, and the role of high folate 
intake in modulating these effects were investigated in male 
fetal livers. Arsenic exposure alone had little effect on DNA 
methylation in fetal livers while when accompanied by the 
administration of high folate, the CpG island methylation 
changed in 2,931 genes. Most of these genes were associ-
ated with neurodevelopment, cancer, cell cycle, and signal-
ing networks (Tsang et al. 2012). Furthermore, arsenic in 
utero exposure was able to induce hypomethylation in Er-  
gene and in CpG-rich regions of liver of adult and newborn 
mice (Waalkes et al. 2004; Xie et al. 2007).
To ascertain whether perturbation of methylation plays 
a role in arsenic-induced carcinogenesis, the degree of 
methylation of TP53 and p16 genes in DNA obtained from 
blood samples of people chronically exposed to arsenic 
and skin cancer subjects was studied (Chanda et al. 2006). 
Significant DNA hypermethylation of promoter region of 
Fig. 2  One-carbon metabolism is a critical pathway centered around 
folate and has a central role in DNA synthesis, in substrates meth-
ylation, and in glutathione synthesis. Notes: –CH3: methyl group; 
5-methylTHF: 5-methyltetrahydrofolate; 5,10-methyleneTHF: 
5,10-methylentetrahydrofolate; AS3MT: arsenite methyltransferase; 
CBS: cystathionine b-synthase; DHF: dihydrofolate; DNMTs: DNA 
methyltransferases; DMA: dimethylarsinic acid; dTMP: deoxythymi-
dine monophosphate; dUMP: deoxyuridine monophosphate; GSH: 
glutathione; Hcy: homocysteine; iAS: inorganic arsenic; MATs: 
methionine adenosyl transferases; MMA: methylarsonic acid; MTR: 
methionine synthase; SAH: S-adenosylhomocysteine; SAM: S-aden-
osyl methionine; THF: tetrahydrofolate; TYMS: thymidylate syn-
thetase; X: substrate that can be methylated
Arch Toxicol 
1 3
TP53 gene, showing a dose–response relationship, was 
observed in DNA of arsenic-exposed people compared to 
control subjects. Further, hypermethylation of TP53 gene 
was also observed in arsenic-induced skin cancer patients 
compared to subjects having skin cancer unrelated to arse-
nic, at nonsignificant level. Significant hypermethylation of 
p16 gene was also observed in cases of arsenicosis exposed 
to high level of arsenic (Chanda et al. 2006). Majumdar and 
colleagues (Majumdar et al. 2010) found a statistically sig-
nificant increase in DNA methylation level for exposures 
to 250–500 µg/l of arsenic in drinking water, but a global 
hypomethylation for concentrations < 500 µg/l. This can 
be explained in terms of increase in hypermethylation with 
increasing arsenic dose until 500 µg/l. Over this concen-
tration, there is probably too much methionine requirement 
for arsenic biotransformation and excretion, and the extent 
of hypermethylation is no longer statistically significant 
because of the reduced SAM level (Majumdar et al. 2010). 
In human bladder cancer, relatively low levels of arsenic 
exposure have been associated with hypermethylation of 
RASSF1A and PRSS3 (Marsit et al. 2006a) and with hypo-
methylation of LINE1 (Wilhelm et al. 2010). A study of a 
large number of human bladder tumors that have examined 
hundreds of genes demonstrated a relationship in promoter 
methylation profiles with arsenic exposures, suggesting 
that more highly methylated tumors come from individuals 
with larger drinking water arsenic exposures, and that these 
tumors were more aggressive (Wilhelm-Benartzi et al. 
2010). In a study on human liver cancer seemed that a low 
concentration of As2O3 induced CpG island demethylation 
of tumor suppressor genes (p16, RASSF1A, E-cadherin, 
and GSTP1) by inhibition of DNMT activity that reacti-
vated the partially/fully silenced genes in liver cancer cells, 
suggesting that epigenetic changes of tumor suppressor 
genes such as p16 and RASSF1A are involved in the arse-
nic-induced liver carcinogenesis (Cui et al. 2006a).
It is known that death-associated protein kinase (DAPK) 
genes are closely involved in the apoptotic cycle and serve 
as upstream regulators of TP53 target genes. It can be 
hypothesized that alteration of DAPK promoter methyla-
tion is involved in the carcinogenesis of arsenic-induced 
urothelial carcinoma in areas contaminated by arsenic. 
For this reason was conducted a study in order to deter-
mine whether hypermethylation of DAPK gene is associ-
ated with chronic arsenic exposure (Chen et al. 2007). The 
authors observed a significant DNA hypermethylation of 
the promoter region of the DAPK gene in DNA of arsenic-
exposed compared with non-exposed subjects. They also 
demonstrated that aberrant promoter hypermethylation is 
associated with suppressed DAPK protein expression in 
urothelial carcinoma. This indicates that hypermethylation 
is correlated with down-regulation or loss of DAPK protein 
expression, resulting in DAPK inactivation at the protein 
level. The high frequency of loss of DAPK protein expres-
sion in urothelial carcinoma and the involvement of meth-
ylation in this process raise the possibility that this media-
tor of cell death may function as a tumor suppressor gene 
(Chen et al. 2007).
Pilsner et al. (2007) found a positive association 
between urinary arsenic and DNA hypermethylation in 
PBL of Bangladeshi adults chronically exposed to arse-
nic. This effect was modified by plasma folate concentra-
tion, suggesting that arsenic-induced increases in DNA 
methylation cannot occur in the absence of adequate folate 
intake (Pilsner et al. 2007). The same authors found out 
that individuals with global DNA hypomethylation were 
more likely to have skin lesions (Pilsner et al. 2009). In 581 
elderly men exposed to low levels of arsenic was found that 
LINE-1 DNA methylation tended to decrease while Alu 
DNA methylation tended to increase with increasing arse-
nic (Lambrou et al. 2012). Folate nutritional status modi-
fied the association between arsenic and Alu DNA methyla-
tion. In particular, men with lower values of plasma folate 
showed an increase in Alu DNA methylation with increas-
ing arsenic, whereas a decrease was observed among men 
with higher values of plasma folate. On the other hand, no 
differences in the association of arsenic with LINE-1 DNA 
methylation were observed in people with lower or higher 
values of B vitamins. This suggests a potential role for 
nutritional factors in arsenic toxicity.
Methylation levels of tumor suppressor gene p16, of the 
DNA repair gene hMLH1, and of the repetitive elements 
LINE1 were measured in blood DNA of 202 Argentinean 
women (arsenic concentration in drinking water 250 µg/l) 
(Hossain et al. 2012). Arsenic concentration was positively 
associated with methylation of p16 and hMLH1 but not 
with LINE1. The increase in DNA hypermethylation of 
p16 promoter was also observed in arseniasis patients com-
pared with people with no history of arsenic. Furthermore, 
urinary arsenic and arsenic were positively associated with 
p16 methylation, and DMA was negatively associated with 
p16 methylation while MMA had no effect on p16 meth-
ylation. The authors also observed that carriers of the slow-
metabolizing AS3MT haplotype were associated with more 
p16 methylation. Recently, a study on 103 Argentinean 
women (arsenic concentrations in drinking water 250 µg/l) 
found that the AS3MT haplotype, associated with more effi-
cient arsenic metabolism, was associated with increased 
methylation of AS3MT and also with differential methyla-
tion of several genes within about 800 kilobase pairs (Eng-
ström et al. 2013).
Among the most intriguing recent data is the genome-
wide methylome study of PBL DNA of a population in 
Mexico. This study employed an assay that interrogated the 
CpG islands in over 14,000 genes, to uncover an “interac-
tome” complex of 17 hypermethylated tumor suppressor 
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genes in the exposed population. The so-called tumor sup-
pressorome included genes involved in cancers of tissues 
known to be target of arsenic exposure, demonstrating that 
a large number of genes are epigenetically modified in the 
lymphocyte DNA of individuals exposed to arsenic. The 
identified methylation sites could serve as biomarkers of 
adverse health effects in human (Smeester et al. 2011).
It must also be remembered that embryonic and fetal 
development represent a critical period during which nutri-
ent availability as well as environmental stressors, including 
toxicant exposures, have great potential to affect the epige-
netic reprogramming. These effects can not only have impli-
cations for proper development but perhaps even lifelong 
conditioning and health (Gluckman et al. 2008; Li 2002). 
Some studies were conducted on cord blood of arsenic-
exposed newborns or infants. Results showed hypermeth-
ylation of LINE-1 and TP53 promoter region for arsenic 
concentrations in drinking water up to 10 µg/l (Intarasuna-
nont et al. 2012) and no change in methylation of TP53 but 
hypermethylation of LINE-1 and p16 promoter region for 
concentrations up to 230 µg/l (Kile et al. 2012). Hypermeth-
ylation of the whole genome (Pilsner et al. 2012) was also 
found as well as hypomethylation of ESR1 and PPARGC1A 
(Koestler et al. 2013) for drinking water arsenic concentra-
tion up to 1,000 µg/l and up to 100 µg/l, respectively.
Histone tails modifications and altered miRNA expression
The most abundant proteins associated with DNA are his-
tones. Histones aggregate each other forming the histonic 
octamer, around which DNA is wrapped creating the nucle-
osome. The N-terminal tide of histones may undergo many 
changes promoted by specific enzymes, which give rise to 
acetylation, methylation, phosphorylation, cytrullination, 
and ubiquitination (Kouzarides 2007). These changes influ-
ence the chromatin structure facilitating gene transcription, 
its inhibition or other important mechanisms (Shia et al. 
2006). To date, published studies about arsenic effects on 
histone modifications focused on acetylation, methylation, 
and phosphorylation (Table 6).
Histone acetylation
This type of modification, dynamic and reversible, is the 
base of gene expression (Glozak and Seto 2007). It is regu-
lated by two classes of antagonist enzymes: histone acetyl-
transferases (HATs) (Sterner and Berger 2000) and histone 
deacetylase (HDACs) (Cress and Seto 2000). In this modi-
fication, using as a donor the acetyl coenzyme A, an acetyl 
group is transferred on an amino acid residue of lysine, 
which looses the ability to bind with a high affinity, the 
DNA phosphate groups. By this way, DNA is relaxed ena-
bling other proteins and enzymes to interact with it. Jensen 
et al. (2008) demonstrated that malignant transformation of 
human urothelial cells by arsenicals is also associated with 
changes in histone acetylation in gene promoter regions. 
Malignant transformations induced by As3 and MMA3 
seem to be arsenic-specific because they are significantly 
more frequent than those occurring randomly. These data 
suggest that epigenetic remodeling is linked to malignant 
transformation associated with chronic and environmen-
tally relevant exposure to As3 and MMA3. H4K16 is usu-
ally hypoacetylated in human tumors, thus a loss of H4K16 
may play a role in the pathogenesis of different human 
cancers. Jo et al. (2009) showed that, in human bladder 
epithelial cells, MMA3 and As3 reduced H4K16 in a dose- 
and time-dependent manner suggesting that a reduction 
in H4K16 acetylation caused by chronic arsenic exposure 
could be detrimental and contribute to bladder carcinogen-
esis. Moreover, they showed that knockdown of MYST1, 
responsible for H4K16 acetylation, increased cytotoxicity 
from arsenical exposures in human bladder epithelial cells. 
They also demonstrated that As3 exposure induces elevated 
histone acetylation (Li et al. 2002, 2003), and this is prob-
ably mediated by HDACs that are in turn inhibited by As3 
(Ramírez et al. 2008).
Histone methylation
In this reversible modification, a methyl group is trans-
ferred to a lysine or an arginine present on the N-termi-
nal end of H3 or H4. As3 treatment can lead to different 
effects on the methylation of H3 lysine residues. Zhou et al. 
(2008), in fact, published the first evidence that arsenite 
can disrupt the epigenetic machinery that regulates histone 
modifications and found that arsenite can modulate the 
methylation of histone H3. They reported that human lung 
carcinoma A549 cells, exposed to inorganic trivalent arse-
nic (arsenite) increased H3K9 dimethylation (H3K9me2) 
and decreased H3K27 trimethylation (H3K27me3). A year 
later, Zhou et al. (2009) showed that 1 µM arsenite signifi-
cantly increased H3K4me3 after 24-h or 7-day exposures 
in human lung carcinoma A549 cells. It was also showed 
that elevated K3K9me2 is involved in the silencing of 
tumor suppressors in the cancer cell lines (Esteve et al. 
2007; McGarvey et al. 2006).
Histone phosphorylation
This modification occurs in H2A, H2B, H3 e H4 N-termi-
nal region, while H1 can be posttranslationally modified 
by this reaction. It was suggested that H3 phosphorylation 
induced by arsenic exposure might be responsible for the 
up-regulation of the oncogenes c-Fos and c-Jun (Li et al. 
2003) and the induction of a protoapoptotic factor, CAS-
PASE 10 (Li et al. 2002).
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Two modifications of histone H3, dimethylation H3K4 
and acetylation of H3K9 and H3K14, are associated with 
transcriptional competency, whereas the other two modi-
fications of histone H3, trimethylation of H3K27 and 
dimethylation of H3K9, are correlated with transcriptional 
repression (Peterson and Laniel 2004). It was showed that 
different types of histone modifications affect gene regula-
tion and expression in a coordinate manner. WNT5A gene 
expression is up-regulated in As3- and MMA3-induced 
malignant transformation in uroepithelial cells in associa-
tion with the enrichment of permissive histone modifica-
tions and reduction in the WNT5A promoter region (Jensen 
et al. 2009).
MicroRNAs (miRNAs) are endogenous small noncoding 
RNAs that regulate gene expression in a sequence-specific 
manner. They have been implicated in the etiology, pro-
gression, and prognosis of cancer, and many studies have 
shown that profiles of miRNA expression differ between 
normal and tumor tissues and among tumor types (He and 
Hannon 2004; Lu et al. 2005). Several studies found cor-
relation between arsenic exposure and altered miRNA 
expression (Table 7).
Marsit et al. (2006b) investigated the role that folate 
deficiency and arsenic play in miRNA expression. They 
treated human lymphoblast TK6 cells with 2 µmol/l of 
Na3AsO3 for 6 days. They observed an altered expression 
of five miRNAs (in particular a decline of sixfold of miR-
210) when compared to untreated cells; the same results 
were observed when the cells were grown in folate-defi-
cient media. It was not observed a decrease in global meth-
ylation between treated and control cells. Furthermore, the 
alteration of the miRNA expression is a reversible pro-
cess, in fact following the removal of stress conditions, the 
miRNA levels returned to normal levels.
Cao et al. (2011) evaluated the relationship between 
miRNAs and As2O3 treatment using T24 human blad-
der carcinoma cells. The microarray analysis identified 67 
miRNAs that were up- or down-regulated in T24 cells fol-
lowing arsenic treatment.
Wang et al. (2011) investigated the role of miRNAs in 
arsenic-induced human bronchial epithelial cell malignant 
transformation and tumor formation. They found that pro-
longed exposure of immortalized TP53-knocked down 
human bronchial epithelial cells [TP53(low)HBECs] to 
Table 6  Arsenic exposure and histonic modifications
NA not available
Histonic modification Model As exposure Evidences References
Acetylation NB4 cells As3 (conc. NA) Acetylation of lysine 14 residue Li et al. (2002)
Lung fibroblast WI-38 cells As3 (conc. NA) Acetylation of H3 Li et al. (2003)
Urothelial cells As3 (conc. NA) H3 acetylation in gene promoter 
regions
Jensen et al. (2008)
UROtsa cells 1, 3, and 10 µM (As3) and 0.3, 1, 
and 3 µM (MMA3)
Reduction of H4K16 acetylation 
in a dose- and time-dependent 
manner
Silencing of MYST1
Jo et al. (2009)
Methylation Lung carcinoma A549 cells 2.5 and 5 µM As3 (1–10 µM 
arsenite correspond to 250–
1,000 µg/l As exposure)
Increase of H3K9 dimethylation
Decrease of H3K27 trimethyla-
tion
Increase of global level of H3K4 
trimethylation
Zhou et al. (2008)
0.1 µM As3 Increase of H3K4 di-and trimeth-
ylation
Increase of H3K36 trimethylation
Increase of H3K9 mono- and 
dimethylation
Decrease of H3K36 dimethyla-
tion
Lung carcinoma A549 cells 1 and 5 µM As3 Increase of H3K4 di-and trimeth-
ylation
Decrease of H3K4 monomethyla-
tion
Increase of H3K4 trimethylation
Zhou et al. (2009)
Phosphorylation NB4 cells 0.1, 0.5, and 1 As3
As3 (conc. NA)
Increase of H3 phosphoacetyla-
tion at the CASPASE-10 gene
Li et al. (2002)
Lung fibroblast WI-38 cells As3 (conc. NA) Increase of H3 phosphorylation in 
a time-dependent manner
Li et al. (2003)
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low levels of arsenite (Na3AsO3, 2.5 µM) caused malig-
nant transformation that was accompanied by epithelial-to-
mesenchymal transition (EMT) and reduction in the levels 
of miR-200 family members. Stably re-expressing miR-
200b in arsenite-transformed cells [As-TP53 (low) HBECs] 
completely reversed their transformed phenotypes. Ling 
et al. (2012) observed that during arsenite-induced trans-
formation of human embryo lung fibroblast (HELF) cells, 
miR-21 was up-regulated and the extracellular signal-
regulated kinase (ERK)/nuclear factor-kB (NF-kB) signal 
pathway (pathway activated by ROS) was activated. Fur-
ther, anti-miR-21 down-regulated miR-21 expression and 
prevented the arsenite-induced activation of ERK via the 
increase in Spry1 (a target protein of miR-21). This indi-
cates that miR-21 has a feedback effect in regulating ERK 
activation. Thus, the transformation of HELF cells induced 
by exposure to arsenite is mediated by increased miR-21 
expression, which, in turn, promotes the activation of the 
ERK/NF-kB pathway.
miRNAs expression was also evaluated in fertilized eggs 
injected via the yolk sac with 100 nM Na3AsO3. Microarray 
analyses revealed that the expression of a set of miRNAs 
changed after arsenite administration, especially miRNA-
9, 181b, 124, 10b, and 125b, which exhibited a massive 
decrease in expression. Integrative analyses of the micro-
array data revealed that several miRNAs, including miR-9 
and miR-181b, might target several key genes involved in 
arsenic-induced developmental toxicity (Cui et al. 2012). A 
recent study provided evidence that arsenic is also able to 
induce overexpression of miR-2909, a miRNA involved in 
the regulation of Cyclin D1 gene expression, of the apop-
tosis antagonizing transcription factor (AATF) and B-cell 
lymphoma 3 (BCL3) (Sharma et al. 2013).
Unifying hypothesis on arsenic carcinogenicity
The literature shows that arsenic can induce several types 
of cancer in population living in areas with high arsenic 
concentration in drinking water (up to 3,000 µg/l), while 
evidences for arsenic-induced carcinogenicity in animals 
are limited (Huff et al. 1998, 2000; Kitchin 2001; NRC 
1999, 2001). Arsenic is also able to induce both genome 
damage and epimutations in in vitro and in in vivo model 
systems as well as in human populations exposed to arse-
nic. A paper we reported, in fact, showed that the presence 
of CA, marker of genomic instability and of early biologi-
cal effects of carcinogen exposure, in PBL of populations 
exposed to arsenic in well water, is higher in people with 
neoplastic skin diseases with respect to non-cancerous skin 
lesions individuals (Ghosh et al. 2007). This suggests that 
arsenic induces CA, and this induction is strongly corre-
lated with cancer. The role of CA as valuable biomarker, 
predictor of cancer occurrence, was demonstrated in a 
pooled cohort study by Bonassi et al. (2008). Arsenic can 
induce gene promoter hyper-/hypomethylation leading to 
deregulation or loss of gene function. In particular, arsenic 
can induce hypermethylation of tumor suppressor genes 
such as TP53 (Chanda et al. 2006; Intarasunanont et al. 
2012; Kile et al. 2012; Mass and Wang 1997), RASSF1A 
(Cui et al. 2006a; Marsit et al. 2006a), p16 (Chanda et al. 
2006; Cui et al. 2006a; Hossain et al. 2012; Kile et al. 
2012), and hMLH1 (Hossain et al. 2012), and hypometh-
ylation of the oncogene c-Myc (Chen et al. 2001) (Table 5). 
Regarding global DNA methylation, in vitro and animal 
studies showed that arsenic induces global DNA hypo-
methylation (Chen et al. 2004; Zhao et al. 1997), a typi-
cal feature of cancer (O’Hagan et al. 2011) probably due to 
SAM consumption (Table 5). Results from human studies 
showed both an increase in DNA methylation level (expo-
sure level 250–500 µg/l) and a reduction of genomic meth-
ylation (arsenic exposure level >500 µg/l) (Majumdar et al. 
2010). Another study found that DNA methylation degree 
could be modified by plasma folate concentration (Pilsner 
et al. 2007). Particularly, the increase in DNA methylation 
induced by arsenic cannot occur in the absence of adequate 
folate plasma levels. Aside from the work of Marsit et al. 
(2006a), the analyses of these studies were performed in 
Table 7  miRNA alterations mediate by arsenic
"  Increase, # decrease
Epigenetic changes Tissues/species References
#miR-210
"miR-22, miR-34a, miR-221, miR-222
Human lymphoblast TK6 cells treated with 2 µmol/l of Na3AsO3 Marsit et al. (2006b)
#miRNA-19a
"miRNA-222
T24 human bladder carcinoma cells Cao et al. (2011)
#miR-200 family members TP53 low HBECs cells (2.5 µM of Na3AsO3) Wang et al. (2011)
"miR-21 Human embryo lung fibroblast cells Ling et al. (2012)
#miRNA-9,181b, 124, 10b, 125b Fertilized eggs injected via the yolk sac with 100 nm Na3AsO3 Cui et al. (2012)
"miR-2909 Human peripheral blood mononuclear cells Sharma et al. (2013)
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PBL and further studies are required to determine whether 
arsenic exposure has different effects on DNA methylation 
status across different tissues.
Therefore, it seems that arsenic may predispose the cell 
to carcinogenesis through several pathways related to both 
genetic and epigenetic mechanisms. These mechanisms are 
not separate events; they are intertwined and benefit from 
each other during the carcinogenesis multistep process 
(You and Jones 2012; Sadikovic et al. 2008). Genetic modi-
fications in epigenetic regulators lead to epigenetic changes 
such as aberrant DNA methylation, histone modifications, 
and miRNA altered expression as well as modifications in 
epigenetic mechanisms can lead to genetic modifications 
and hence to carcinogenicity (You and Jones 2012). There-
fore, a possible mechanism involved in arsenic-induced 
carcinogenesis could result from its capacity to induce both 
genotoxic effects and epigenetic deregulation. This “double 
capacity” can induce genome instability and deregulation 
of crucial genes, such as oncogenes and tumor suppressor 
genes, which are hallmarks of several types of cancer (Len-
gauer et al. 1997; You and Jones 2012).
For example, Sciandrello et al. (2004) observed that 
arsenic induced chromosomal instability, as a consequence 
of global DNA methylation reduction. Another study 
showed that arsenic induces high micronuclei frequency, 
through its aneuploidogenic properties (Colognato et al. 
2007). It was also reported that the capacity of arsenic to 
induce aneuploidy was abolished following the adminis-
tration of SAM to cell cultures, suggesting that a reduced 
methylation capacity of the cells may promote chromo-
some missegregation (Ramírez et al. 2007). Furthermore, 
hypomethylation of centromeric DNA results in chromo-
some loss, as well as breakage of specific chromosomes, 
such as chromosomes 1, 9, and 16 (Tuck-Muller et al. 
2000). Heit et al. (2009) treated HeLa cells with a meth-
ylation inhibitor and observed less compact pericentric 
chromatin, accompanied by demethylation of H3K9 and 
H4K20 and with consequent chromosome missegregation 
induction (Heit et al. 2009). Probably, the ability of arsenic 
to induce global DNA demethylation through SAM con-
sumption leads to defects in heterochromatin integrity in 
centromeric regions affecting microtubule attachment and 
improper microtubule–kinetochore connections resulting in 
aneuploidogenic events.
Arsenic also exerts its “double capacity” through ROS 
production during its biotransformation (Yamanaka et al. 
2004). From a genotoxic point of view, ROS induce DNA 
single-strand breaks (ssDNA) either directly, attacking 
DNA bases, or indirectly, during the course of base excision 
repair (BER) mechanisms (Kligerman et al. 2010; Mourón 
et al. 2006). It was observed, in fact, that ROS scavengers 
were able to suppress arsenic-induced oxidative stress and 
its genotoxic effects in cells (Flora 1999; Liu et al. 2001). 
Considering epigenetic effects, it is well established that 
ROS induce DNA methylation imbalance (Franco et al. 
2008; Patchsung et al. 2012; Ziech et al. 2011). In oxidative 
stress condition, the antioxidant GSH is highly consumed 
and for its resynthesis is induced slowdown of methione 
cycle and depletion of SAM (Hitchler and Domann 2009). 
Oxidative lesions, such as 8-OHdG, may introduce a G-T 
transversion resulting in the loss of CpG sites (Kuchino 
et al. 1987). Moreover, the presence of 8-OHdG in CpG 
dinucleotides can strongly inhibit the methylation at the 
adjacent cytosine residues (Weitzman et al. 1994). It was 
also proposed that methylation of cytosine residues impairs 
the capacity of repairing adjacent oxidized guanine bases 
(Zawia et al. 2009). ROS can generate 5-hydroxymethyl-
cytosine (5hmC) by oxidation of 5-methylcytosine. 5hmCs 
are characterized by poor affinity for DNMT enzymes and 
for methyl-CpG-binding protein 2 (MeCP2), a critical epi-
genetic regulator that recruits cytosine methyltransferases 
and histone deacetylase (Valinluck et al. 2004). There are 
studies reporting that ROS can interact with histone dea-
cetylases and DNA methyltransferases leading to the meth-
ylation of specific gene promoters, such as E-cadherin, a 
tumor suppressor gene (Lim et al. 2008), or the extracellu-
lar superoxide dismutase SOD3 (Zelko et al. 2011).
In summary, arsenic can induce carcinogenicity through 
several modes of action (Fig. 3). When arsenic enters the 
cell, its biotransformation leads to one-carbon metabolism 
imbalance (SAM consumption, inhibition of DNA repair, 
and GSH consumption) and ROS production. As a result, 
the genome is induced to counteract mutations and epimu-
tations such as DNA strand breaks, DNA repair impair-
ment, induction of 5hMC, and methylation inhibition that 
probably are all able to induce carcinogenesis. The inacti-
vating mutations in genes that control the epigenome have 
the potential to disrupt DNA methylation patterns, histone 
modifications and miRNA expression, and consequently 
gene expression. Aberrant epigenetic processes can cause 
point mutations, for example inhibiting the expression of 
DNA repair gene expression.
Therefore, the “double capacity” of arsenic to cause 
genotoxicity and epimutations induces genomic instability 
and altered genes expression that lead to carcinogenic cel-
lular processes.
Concluding remarks
Arsenic is a human carcinogen that induces tumors through 
mechanisms not yet completely understood. Elevated con-
centrations of inorganic arsenic in drinking water pose 
a public health threat to millions of people worldwide. 
Reviewed literature indicates that the main mechanisms by 
which inorganic arsenic causes negative health effects are 
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induction of genotoxicity, oxidative stress, and inhibition 
of DNA repair (Rossman et al. 2001). A growing body of 
evidence indicates that epigenetic modifications have a role 
in arsenic-inducing adverse effects on human health. Epi-
demiological studies show that arsenic induces genotoxic 
effects acting both as a clastogen and as an aneuploidogen. 
In vitro studies show that arsenic induces MN, CA, and 
SCE in several different cell types (Tables 2, 3) and that 
the different metabolites of arsenic induced different effects 
(Colognato et al. 2007; Dopp et al. 2005) Arsenic can also 
induce MN, CA, and SCE in animal models at different 
doses and in different modes of administration (Table 3). In 
epidemiological studies (Table 4), CA and MN result the 
main biomarkers of genotoxic effects induced by arsenic 
detectable in PBL and bladder cells.
Arsenic induces epimutations both at a genome-wide 
level and at specific gene promoter regions (Table 5), and 
is also able to induce histone modifications such as meth-
ylation, acetylation, and phosphorylation of histone tails, 
changing the expression of several genes (Table 6). Fur-
thermore, several investigators observe that the exposure to 
arsenic induces gene-specific alteration of miRNA expres-
sion (Table 7) likely resulting in an impaired expression 
of all the genes whose expression is regulated by those 
miRNAs.
While there exist several in in vitro and in in vivo inves-
tigations on arsenic-induced epigenetic effects, there are 
only few studies reporting these effects on large popula-
tions exposed to arsenic in drinking water.
These considerations bring us back to the concept of 
epigenetic epidemiology defined as the study of the asso-
ciation between epigenetic variation and the risk of disease 
in humans (Waterland and Michels 2007). The combination 
of the two sciences (epidemiology and epigenetic) creates 
a science that supports the role of epigenetic modifications 
in the etiology of human diseases and the understanding 
of epigenetics as a possible mechanism that underlines the 
link between exposure and outcome of the disease (Michels 
Fig. 3  Possible molecular 
mechanisms used by arsenic to 
induce carcinogenesis
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2010). Environmental agents can in fact modify gene 
expression through epigenetic processes. The epigenetic 
modifications are defined as mitotically heritable chemi-
cal and structural changes. These modifications are prob-
ably the gene–environment interaction mediators because 
genetic factors may alter the epigenetic response to the 
environment (Bjornsson et al. 2004).
The epigene–environment interactions can be gene-spe-
cific or involve larger components of the genome, and some 
gene–environment interactions can affect the epigenetic 
profile (e.g., effect of folate on the risk of several cancers). 
Epigenetic epidemiology can provide new opportunities to 
identify disease biomarkers and be useful in discovering 
pathways for links between environmental exposures and 
disease outcomes (Michels 2010). For all these reasons, 
epidemiological studies on population arsenic-exposed 
should be designed in order to examine more comprehen-
sively the presence and the consequence of these epigenetic 
alterations.
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